Intranasal neurological therapeutics

A faster, non-invasive route to the brain.

Blitz BioPharma is developing spray-dried intranasal formulations and a precision delivery device designed to reach the brain directly, starting with Parkinson's disease.

Explore the platformPartner with us
Nose-to-brainDesigned to bypass the blood-brain barrier
Spray-dried powderTemperature-stable formulations
Precision deviceHigh-velocity, rifled airflow
Lead programParkinson's disease
01  Platform

Overcoming the barriers to brain drug delivery

Most neurological drugs struggle to reach the brain in effective amounts. Our platform pairs a dry-powder formulation with a purpose-built nasal device to address that directly.

01

High-velocity delivery

A proprietary airflow system produces rifled, high-velocity dispersion for precise targeting of the nasal cavity.

02

Rapid brain transport

Designed to enable drug transport toward the brain within minutes via neural and vascular pathways.

03

Optimized absorption

Temperature-stable spray-dried powders are designed to enhance absorption through the nasal lining.

What the approach is designed to enable

  • Direct access to the brain, bypassing the blood-brain barrier
  • Therapeutic effect at lower doses than conventional routes
  • Reduced systemic exposure and drug-drug interactions
  • Non-invasive use in acute field settings and at home

Limits of today's treatments

  • Systemic toxicity of current drugs
  • Poor compliance driven by side effects and invasive delivery
  • Limited effectiveness of drugs that fail to cross the blood-brain barrier
  • Breakdown in the gut and liver reduces the dose reaching the brain
02  Pipeline

Parkinson's first, then a broader neurology franchise

Our lead program applies the platform to Parkinson's disease, with additional formulations and drug-device combinations to follow.

ProgramIndicationApproachStage
BLZ-PDParkinson's diseaseSpray-dried intranasal formulation with precision device. Aims to address "off" periods and motor fluctuations.To be confirmed
BLZ-NeuroAdditional neurological indicationsExpanded formulations and drug-device combinations on the same platform.To be confirmed
A

Rapid, precise action

Intranasal delivery is designed to reach subcortical target areas quickly.

B

Targeted regulation

Aims to target dopamine regulation and inflammation to reduce motor fluctuations.

C

Tolerability

Intended to avoid the gastrointestinal and central side effects seen with other routes.

Blitz BioPharma's programs are investigational and have not been approved by the FDA or any regulatory authority. Parkinson's market estimate ($5.3B): source and year to be cited before publication.

03  Company

Built in Atlanta for patients who need a better option

Blitz BioPharma is a neurological drug-delivery company headquartered in Atlanta, Georgia. We are open to development, licensing and investment conversations.

Mission

Reach the brain faster

Make effective neurological therapy non-invasive, rapid and usable outside the clinic.

Team

Founders

Leadership profiles to be added once approved for external use.

Partnering

Open to collaboration

Development, licensing and strategic investment inquiries are welcome.

04  Contact

Partner with Blitz BioPharma

Tell us about your interest and we will respond promptly.

Emailinfo@blitzbiopharm.com

LocationAtlanta, Georgia

ForPartnering, licensing and investor inquiries

Send message